Previous 10 | Next 10 |
2023-09-12 13:26:27 ET More on Reata Pharmaceuticals Seeking Alpha’s Quant Rating on Reata Pharmaceuticals Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward San...
2023-09-11 07:19:20 ET Summary This article provides a follow-up study reviewing the 6-month performance of the top "zombie" firm portfolio selections based on Federal Reserve metrics. Three different model returns from March are reviewed, with sample stock portfolios down -23.4%,...
2023-09-10 15:17:31 ET HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its “buy” ratings list. IQVIA ( NYSE: IQV ) and Zoetis ( NYSE: ZTS ) were labeled “quality growthȁ...
2023-09-09 07:45:00 ET As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. When all's said and done, the move w...
2023-09-07 07:08:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharma stocks can be a great way to add profits to your investment account. Companies that make lifesaving medications or develop treatments to ease symptoms can be true moneymakers. Finding th...
2023-09-01 18:29:00 ET More on Biogen Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Sanofi was mystery suitor in Reata Pharma bidding war - report Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment...
2023-08-30 05:20:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of seve...
NEW YORK, NY / ACCESSWIRE / August 22, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Reata Pharmaceuticals, Inc. (...
NEW YORK, NY / ACCESSWIRE / August 17, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Fiesta Restaurant Group, Inc. (NASD...
2023-08-15 16:20:35 ET More on Reata Pharmaceuticals Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone D...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023